Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 7:14:1090533.
doi: 10.3389/fimmu.2023.1090533. eCollection 2023.

Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials

Patrick M McCarthy  1 , Franklin A Valdera  1 , Todd R Smolinsky  1 , Alexandra M Adams  1 , Anne E O'Shea  1 , Katryna K Thomas  1 , Spencer Van Decar  1 , Elizabeth L Carpenter  1 , Ankur Tiwari  2 , John W Myers  3 , Diane F Hale  1 , Timothy J Vreeland  1 , George E Peoples  4 , Alex Stojadinovic  4 , Guy T Clifton  1
Affiliations

Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials

Patrick M McCarthy et al. Front Immunol. .

Abstract

Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated inconsistency in assessing the efficacy of cancer vaccination. Tumor infiltrating lymphocytes (TILs), reflect the local tumor microenvironment and may prove a superior endpoint in cancer vaccination trials. Cancer vaccines may also promote success in combination immunotherapy treatment of weakly immunogenic tumors. This review explores the impact of TILs as an endpoint for cancer vaccination in multiple malignancies, summarizes the current literature regarding TILs analysis, and discusses the challenges of providing validity and a standardized implementation of this approach.

Keywords: cancer vaccine; checkpoint inhibition; endpoint; immunotherapy; tumor infiltrating lymphocyte (TIL); vaccination.

PubMed Disclaimer

Conflict of interest statement

GP is employed by Orbis Health Solutions and Cancer Insight; is a consultant for Rapamycin Holdings, Heat Biologics, Abexxa Biologics, and Pelican Therapeutics; and has received funding from the above as well as Sellas Life Sciences and Genentech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Figure adapted from recent Frontiers publication by Bai et al. demonstrating the cellular composition of the tumor microenvironment.
See this image and copyright information in PMC

References

    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst (2000) 92(3):205–16. doi: 10.1093/jnci/92.3.205 - DOI - PubMed
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer (2009) 45(2):228–47. doi: 10.1016/j.ejca.2008.10.026 - DOI - PubMed
    1. Clifton GT, Kohrt HE, Peoples GE. Critical issues in cancer vaccine trial design. Vaccine (2015) 33(51):7386–92. doi: 10.1016/j.vaccine.2015.09.019 - DOI - PubMed
    1. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol (2015) 33(31):3541–3. doi: 10.1200/JCO.2015.61.6870 - DOI - PMC - PubMed
    1. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2010) 59(5):663–74. doi: 10.1007/s00262-009-0782-8 - DOI - PMC - PubMed

Publication types

Substances